Literature DB >> 17390259

Huntington's Disease.

Francis O Walker1.   

Abstract

Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment. It is an autosomal-dominant disorder that has a substantial impact on family structure and dynamics in terms of providing care for affected family members and, for the offspring of an affected parent, dealing with at-risk status. Therapy that slows the progressive neuronal dysfunction or degeneration is unavailable, so pharmacotherapy is currently aimed primarily at managing behavioral and psychiatric symptoms, and, in selected cases, controlling severe chorea. Effective intervention by clinicians is possible, however, in terms of providing patients and families with accurate information about the disease, counseling them about availability of genetic testing at specialized centers, and in giving them sound advice regarding work, driving, relationships, finances, research participation, and support groups.

Entities:  

Mesh:

Year:  2007        PMID: 17390259     DOI: 10.1055/s-2007-971176

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  71 in total

Review 1.  Neuroinflammation in Huntington's disease.

Authors:  Thomas Möller
Journal:  J Neural Transm (Vienna)       Date:  2010-06-10       Impact factor: 3.575

Review 2.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

Review 3.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

4.  Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.

Authors:  Dénes Zádori; Gábor Nyiri; András Szonyi; István Szatmári; Ferenc Fülöp; József Toldi; Tamás F Freund; László Vécsei; Péter Klivényi
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

Review 5.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

6.  Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

Authors:  Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

Review 7.  Adult neurogenesis in neurodegenerative diseases.

Authors:  Beate Winner; Jürgen Winkler
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

8.  Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.

Authors:  Udo Rüb; Matthias Hentschel; Katharina Stratmann; Ewout Brunt; Helmut Heinsen; Kay Seidel; Mohamed Bouzrou; Georg Auburger; Henry Paulson; Jean-Paul Vonsattel; Herwig Lange; Horst-Werner Korf; Wilfred den Dunnen
Journal:  Brain Pathol       Date:  2014-03-03       Impact factor: 6.508

9.  Prion-like proteins sequester and suppress the toxicity of huntingtin exon 1.

Authors:  Can Kayatekin; Kent E S Matlack; William R Hesse; Yinghua Guan; Sohini Chakrabortee; Jenny Russ; Erich E Wanker; Jagesh V Shah; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 10.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.